Article thumbnail
Location of Repository

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

By Fiona E McCann, Andrew C Palfreeman, Melanie Andrews, Dany P Perocheau, Julia J Inglis, Peter Schafer, Marc Feldmann, Richard O Williams and Fionula M Brennan
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2911898
Provided by: PubMed Central

Suggested articles

Citations

  1. (2005). A: Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev
  2. (2007). Amelioration of collageninduced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
  3. (2010). Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a a model of psoriasis.
  4. (2005). AR: Phosphodiesterase 4 D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell
  5. (2001). Beume R: In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther
  6. (2007). Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem
  7. (2008). C: An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin
  8. (2001). CD: Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties. Biochem Biophys Res Commun
  9. (2007). Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum
  10. (2007). Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol
  11. (1995). Collagen-induced arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity
  12. (1995). Connolly KM: Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol
  13. (1989). Cytokine production in culture by cells isolated from the synovial membrane.
  14. (2007). D: PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.
  15. (1999). Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wallinduced arthritis in rats.
  16. (1994). Esser KM: Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
  17. (2007). FM: Preparation of mononuclear cells from synovial tissue. Methods Mol Med
  18. (1995). Giembycz MA: Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol
  19. (2009). GW: Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.
  20. (1995). Hatzelmann A: PDE isoenzymes as targets for antiasthma drugs. Eur Respir J
  21. (2004). Heeke GV: Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol
  22. (2003). Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther
  23. (1989). Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet
  24. (2005). Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today
  25. (2005). Life after PDE4: overcoming adverse events with dualspecificity phosphodiesterase inhibitors. Curr Opin Pharmacol
  26. (2002). LL: Cyclic nucleotide research -- still expanding after half a century. Nat Rev Mol Cell Biol
  27. (2003). Maini RN: Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med
  28. (2000). MM: Antiinflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.
  29. (1993). Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions
  30. (2000). Molecular diversity of cyclic AMP signalling. Front Neuroendocrinol
  31. (2008). PDE4 inhibitors: current status.
  32. (1994). PJ: Rapid assessment of islet cell viability by MTT assay after cold storage in different solutions. Transplant Proc
  33. (1998). Potential of phosphodiesterase type of IV inhibitors in the treatment of rheumatoid arthritis. IDrugs
  34. (1997). Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
  35. (2004). The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures.
  36. (1993). The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
  37. (1989). UF: Oxpentifylline in endotoxaemia. Lancet
  38. (2006). Virley DJ: Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigrostriatal degeneration.
  39. (2009). VS: Apremilast Is Active in the Treatment of Psoriatic Arthritis (PsA).
  40. (2001). Zutphen LF: Validation of a new system for the automatic registration of behaviour in mice and rats. Behav Processes
  41. (2002). Zvaifler NJ: Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.